Heather Strahl, PA
Medical · Greenville, SCNPI 1497821573
Payments from drug & device makers
Across 197 payments — averaging $17.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$376
- Boehringer Ingelheim$366
- Lilly USA, LLC$299
- Dexcom, Inc.$290
- AbbVie$287
- Abbott$193
- plus $2K from 27 others
What the payments were for
- Food & beverage$3,426100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 22 | $376 |
| Boehringer Ingelheim | 19 | $366 |
| Lilly USA, LLC | 10 | $299 |
| Dexcom, Inc. | 16 | $290 |
| AbbVie | 22 | $287 |
| Abbott | 10 | $193 |
| Amgen | 9 | $182 |
| AstraZeneca | 11 | $153 |
| Pfizer | 10 | $142 |
| Amarin Pharma, Inc. | 8 | $124 |
| Bayer | 8 | $120 |
| Acadia Pharmaceuticals Inc | 6 | $105 |
| Novartis | 5 | $95 |
| Sanofi-aventis U.S. LLC | 4 | $76 |
| Esperion Therapeutics, Inc. | 4 | $66 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $58 |
| Lundbeck LLC | 2 | $54 |
| Daiichi Sankyo Inc. | 3 | $53 |
| GSK | 3 | $51 |
| Astellas Pharma US Inc | 3 | $39 |
| Neurocrine Biosciences, Inc. | 2 | $38 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $37 |
| IBSA Pharma Inc. | 2 | $29 |
| E.r. Squibb & Sons, L.L.C. | 2 | $28 |
| Exact Sciences | 2 | $28 |
| Eisai Inc. | 2 | $27 |
| Inari Medical, Inc. | 1 | $25 |
| Boston Scientific | 1 | $20 |
| Ultragenyx Pharmaceutical Inc. | 1 | $16 |
| Idorsia Pharmaceuticals US Inc | 1 | $15 |
| Shield Therapeutics Inc | 1 | $12 |
| Merck | 1 | $12 |
| Johnson & Johnson | 1 | $11 |
How this compares
$3,426 in reported general payments places this provider in the 75th percentile of 384 medical providers in South Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 62 | $88,170 |
| TrulicityDulaglutide | 27 | $40,575 |
| Tresiba Flextouch U-200Insulin Degludec | 36 | $38,259 |
| JardianceEmpagliflozin | 39 | $31,743 |
| FarxigaDapagliflozin Propanediol | 24 | $26,075 |
| TradjentaLinagliptin | 30 | $19,238 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 23 | $18,356 |
| GlyxambiEmpagliflozin/Linagliptin | 25 | $17,467 |
| LinzessLinaclotide | 27 | $14,305 |
| Tresiba Flextouch U-100Insulin Degludec | 13 | $12,812 |
| MyrbetriqMirabegron | 21 | $12,372 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 12 | $10,961 |
| JanuviaSitagliptin Phosphate | 14 | $9,823 |
| Vilazodone Hcl | 16 | $3,435 |
| Olmesartan Medoxomil | 30 | $1,644 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $376 | $88,17062 claims |
| Boehringer IngelheimJardiance, Tradjenta, Glyxambi | $366 | $68,44894 claims |
| Lilly USA, LLCTrulicity | $299 | $40,57527 claims |
| AstraZenecaFarxiga | $153 | $26,07524 claims |
| AbbVieLinzess, Synthroid | $287 | $15,44248 claims |
| Astellas Pharma US IncMyrbetriq | $39 | $12,37221 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $76 | $10,96112 claims |
| MerckJanuvia | $12 | $9,82314 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 384 medical providers in South Carolina.
Other medical in Greenville
- Laura BuchGreenville$73K
- Cameron PappasGreenville$18K
- Claire DukeGreenville$18K
- Joseph FriddleGreenville$10K
- Katherine SorrelGreenville$9K
- Cameron LindlerGreenville$6K
- Shonda ThriftGreenville$5K
- Christopher ThompsonSpartanburg$78K
- Suzanne SmithWest Columbia$39K
- Stavros ChrysostomidesColumbia$39K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.